ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

1,6900

01-мая-26 16:45:00

15 мин. задержка

Акции

-0,0100

-0,59%

Сегодняшний диапазон

1,6850 - 1,9100

ISIN

N/A

Источник

NASDAQ

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

08 янв 2026 11:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

08 янв 2026 08:30:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

07 дек 2025 08:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology to Present at Upcoming Investor Conferences

18 ноя 2025 11:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

07 ноя 2025 08:15:00 Источник Nasdaq GlobeNewswire
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

30 окт 2025 08:30:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

23 окт 2025 12:30:00 Источник Nasdaq GlobeNewswire
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

03 окт 2025 09:05:00 Источник Nasdaq GlobeNewswire
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

12 сен 2025 08:30:00 Источник Nasdaq GlobeNewswire
ALX Oncology to Participate in Upcoming Investor Conferences in September

29 авг 2025 12:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

19 авг 2025 08:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

12 авг 2025 16:05:01 Источник Nasdaq GlobeNewswire
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

05 авг 2025 08:00:01 Источник Nasdaq GlobeNewswire
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

30 май 2025 08:00:21 Источник Nasdaq GlobeNewswire
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

20 май 2025 08:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

13 май 2025 08:00:01 Источник Nasdaq GlobeNewswire
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

08 май 2025 08:30:00 Источник Nasdaq GlobeNewswire
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

02 май 2025 08:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

25 апр 2025 13:10:00 Источник Nasdaq GlobeNewswire
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

25 апр 2025 09:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.